ABIOMED INC (ABMD) Stock Price, Quote, News and Overview
NASDAQ:ABMD - Nasdaq - US0036541003 - Common Stock - Currency: USD
ABMD Quote, Performance and Key Statistics
381.02
+0.23 (+0.06%)
The current stock price of ABMD is 381.02 USD. In the past month the price increased by 0.8%. In the past year, price increased by 8.18%.
ABMD Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About ABMD
Company Profile
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. The company is headquartered in Danvers, Massachusetts and currently employs 2,003 full-time employees. The firm develops, manufactures and markets its products, which are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. Its products are used in the cardiac catheterization lab or cath lab, by interventional cardiologists and in the heart surgery suite by cardiac surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty, or heart surgery procedures. The firm's Impella device portfolio includes the Impella 2.5, Impella CP, Impella 5.0, Impella LD, Impella 5.5 and Impella RP devices. Its product pipeline includes Impella ECP, Impella XR Sheath, Impella BTR and precardiac. The Impella ECP device is designed for blood flow of greater than three and a half liters per minute. The Impella BTR device is designed to be a heart pump with integrated motors and sensors.
Company Info
ABIOMED INC
22 Cherry Hill Dr
Danvers MASSACHUSETTS 01923 US
CEO: Michael R. Minogue
Employees: 2003
Company Website: https://www.abiomed.com/
Phone: 19787775410.0
ABIOMED INC / ABMD FAQ
What is the stock price of ABIOMED INC today?
The current stock price of ABMD is 381.02 USD. The price increased by 0.06% in the last trading session.
What is the ticker symbol for ABIOMED INC stock?
The exchange symbol of ABIOMED INC is ABMD and it is listed on the Nasdaq exchange.
On which exchange is ABMD stock listed?
ABMD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ABIOMED INC stock?
16 analysts have analysed ABMD and the average price target is 375.36 USD. This implies a price decrease of -1.49% is expected in the next year compared to the current price of 381.02. Check the ABIOMED INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ABIOMED INC worth?
ABIOMED INC (ABMD) has a market capitalization of 17.18B USD. This makes ABMD a Large Cap stock.
How many employees does ABIOMED INC have?
ABIOMED INC (ABMD) currently has 2003 employees.
What are the support and resistance levels for ABIOMED INC (ABMD) stock?
ABIOMED INC (ABMD) has a support level at 380.62 and a resistance level at 381.03. Check the full technical report for a detailed analysis of ABMD support and resistance levels.
Is ABIOMED INC (ABMD) expected to grow?
The Revenue of ABIOMED INC (ABMD) is expected to grow by 10.29% in the next year. Check the estimates tab for more information on the ABMD EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ABIOMED INC (ABMD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ABMD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ABMD, evaluating the profitability, health, valuation and growth aspects
- ABIOMED INC (ABMD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ABIOMED INC (ABMD) Sales and EPS estimates to see what analysts future expectations are.
- ABIOMED INC (ABMD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ABIOMED INC (ABMD) Insider and Institutional Ownership to learn about the owners and their transactions.
- ABIOMED INC (ABMD) Stock Chart to make your own analysis
- ABIOMED INC (ABMD) Latest news and press-releases to stay up to date.
Does ABIOMED INC (ABMD) stock pay dividends?
ABMD does not pay a dividend.
When does ABIOMED INC (ABMD) report earnings?
ABIOMED INC (ABMD) will report earnings on 2023-02-01.
What is the Price/Earnings (PE) ratio of ABIOMED INC (ABMD)?
The PE ratio for ABIOMED INC (ABMD) is 78.72. This is based on the reported non-GAAP earnings per share of 4.84 and the current share price of 381.02 USD. Check the full fundamental report for a full analysis of the valuation metrics for ABMD.
ABMD Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ABMD. When comparing the yearly performance of all stocks, ABMD is one of the better performing stocks in the market, outperforming 96.07% of all stocks.
ABMD Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ABMD. ABMD is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
ABMD Financial Highlights
Over the last trailing twelve months ABMD reported a non-GAAP Earnings per Share(EPS) of 4.84. The EPS decreased by -3.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 24.84% | ||
| ROA | 15.72% | ||
| ROE | 17.32% | ||
| Debt/Equity | 0 |
ABMD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 70% to ABMD. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 3.83% and a revenue growth 10.29% for ABMD